Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens

Journal of Biological Chemistry

Volumn 289, Issue 21, 2014, Pages 14583-14599

  Campos Salinas, Jenny ^a   Cavazzuti, Antonio ^a   O'Valle, Francisco ^b   Forte Lago, Irene ^a   Caro, Marta ^a   Beverley, Stephen M ^c   Delgado, Mario ^a   Gonzalez Rey, Elena ^a,d  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b Medical School of Granada   (Spain)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Biochemistry and Molecular Biology Medical School of Seville ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICROORGANISMS;

ANTI-MICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; CUTANEOUS LEISHMANIASIS; DOCKING SIMULATIONS; GRAM-NEGATIVE BACTERIA; SYNTHETIC ANALOGUES; THERAPEUTIC EFFICACY; VASOACTIVE INTESTINAL PEPTIDE;

PEPTIDES;

UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE 51; VASOACTIVE INTESTINAL POLYPEPTIDE 51[6-30]; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; CELL VIABILITY; COLITIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENDOTOXEMIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; LEISHMANIA MAJOR; MEMBRANE DAMAGE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PARASITE LOAD; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPLEEN CELL;

ANTIMICROBIAL PEPTIDES; BACTERIA; CUTANEOUS LEISHMANIASIS; LIPOPOLYSACCHARIDE (LPS); NEUROPEPTIDE; SEPSIS; VASOACTIVE INTESTINAL PEPTIDE;

AMINO ACID SEQUENCE; ANIMALS; ENDOTOXEMIA; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HYDROGEN BONDING; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84901420727     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.560573     Document Type: Article

References (57)

1. Hotez, P., Raff, S., Fenwick, A., Richards, F., Jr., and Molyneux, D. H. (2007) Recent progress in integrated neglected tropical disease control. Trends Parasitol. 23, 511-514 (Pubitemid 350030912)
2. Hotchkiss, R. S., and Karl, I. E. (2003) The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (Pubitemid 36056721)
3. Augustyniak, D., Nowak, J., and Lundy, F. T. (2012) Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential. Curr. Protein Pept. Sci. 13, 723-738
4. Said, S. I., and Mutt, V. (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169, 1217-1218
5. Vaudry, D., Gonzalez, B. J., Basille, M., Yon, L., Fournier, A., and Vaudry, H. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52, 269-324 (Pubitemid 30368434)
6. Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., Vaudry, D., Vaudry, H., Waschek, J. A., and Said, S. I. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166, 4-17
7. Abad, C., Martinez, C., Juarranz, M. G., Arranz, A., Leceta, J., Delgado, M., and Gomariz, R. P. (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124, 961-971 (Pubitemid 36389799)
8. Delgado, M., Abad, C., Martinez, C., Leceta, J., and Gomariz, R. P. (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7, 563-568 (Pubitemid 32448323)
9. Gonzalez-Rey, E., Fernandez-Martin, A., Chorny, A., Martin, J., Pozo, D., Ganea, D., and Delgado, M. (2006) Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am. J. Pathol. 168, 1179-1188
10. Said, S. I. (1991) Vasoactive intestinal polypeptide: biologic role in health and disease. Trends Endocrinol. Metab. 2, 107-112
11. Onoue, S., Ohmori, Y., Endo, K., Yamada, S., Kimura, R., and Yajima, T. (2004) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur. J. Biochem. 271, 1757-1767 (Pubitemid 38586307)
12. Delgado, M., and Ganea, D. (2003) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 17, 1922-1924
13. Delgado, M., and Ganea, D. (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 17, 944-946
14. El Karim, I. A., Linden, G. J., Orr, D. F., and Lundy, F. T. (2008) Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J. Neuroimmunol. 200, 11-16
15. Delgado, M., Anderson, P., Garcia-Salcedo, J. A., Caro, M., and Gonzalez-Rey, E. (2009) Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ. 16, 406-416
16. Brogden, K. A., Guthmiller, J. M., Salzet, M., and Zasloff, M. (2005) The nervous system and innate immunity: the neuropeptide connection. Nat. Immunol. 6, 558-564 (Pubitemid 41710725)
17. Mayer, M. L., Easton, D. M., and Hancock, R. E. W. (2011) in Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies, Advances in Molecular and Cellular Microbiology, 18th Ed. (Wang, G., ed), pp. 195-220, CABI Publishing, Cambridge, MA
18. Onoue, S., Misaka, S., and Yamada, S. (2008) Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 377, 579-590
19. Onoue, S., Misaka, S., Ohmori, Y., Sato, H., Mizumoto, T., Hirose, M., Iwasa, S., Yajima, T., and Yamada, S. (2009) Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability. Eur. J. Pharm. Biopharm. 73, 95-101
20. Onoue, S., Aoki, Y., Matsui, T., Kojo, Y., Misaka, S., Mizumoto, T., and Yamada, S. (2011) Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats. Int. J. Pharm. 410, 54-60
21. Onoue, S., Matsui, T., Kato, M., Mizumoto, T., Liu, B., Liu, L., Karaki, S., Kuwahara, A., and Yamada, S. (2013) Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability. Eur. J. Pharm. Sci. 49, 382-389
22. Ceraudo, E., Murail, S., Tan, Y. V., Lacapère, J. J., Neumann, J. M., Couvineau, A., and Laburthe, M. (2008) The vasoactive intestinal peptide (VIP) α-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Mol. Endocrinol. 22, 147-155
23. Madeira da Silva, L., Owens, K. L., Murta, S. M., Beverley, S. M. (2009) Regulated expression of the Leishmania major surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins. Proc. Natl. Acad. Sci. U.S.A. 106, 7583-7588
24. Späth, G. F., Lye, L. F., Segawa, H., Sacks, D. L., Turco, S. J., and Beverley, S. M. (2003) Persistence without pathology in phosphoglycan- deficient Leishmania major. Science 301, 1241-1243 (Pubitemid 37052214)
25. Nevot, M., Deroncele, V., López-Iglesias, C., Bozal, N., Guinea, J., and Mercade, E. (2006) Ultrastructural analysis of the extracellular matter secreted by the psychrotolerant bacterium Pseudoalteromonas antarctica NF3. Microb. Ecol. 51, 501-507 (Pubitemid 43962066)
26. Zhang, Y. (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 40
27. Zhang, Y., and Skolnick, J. (2004) Scoring function for automated assessment of protein structure template quality. Proteins 57, 702-710 (Pubitemid 39626992)
28. Trott, O., and Olson, A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461
29. Neurath, M. F., Fuss, I., Kelsall, B. L., Stüber, E., and Strober, W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290
30. Kihara, N., de la Fuente, S. G., Fujino, K., Takahashi, T., Pappas, T. N., and Mantyh, C. R. (2003) Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 52, 713-719 (Pubitemid 36528875)
31. Afonso, L. C., and Scott, P. (1993) Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61, 2952-2959 (Pubitemid 23182292)
32. Ohta, K., Kajiya, M., Zhu, T., Nishi, H., Mawardi, H., Shin, J., Elbadawi, L., Kamata, N., Komatsuzawa, H., and Kawai, T. (2011) Additive effects of orexin B and vasoactive intestinal polypeptide on LL-37-mediated antimicrobial activities. J. Neuroimmunol. 233, 37-45
33. Nikaido, H. (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67, 593-656 (Pubitemid 37549772)
34. Snyder, D. S., and McIntosh, T. J. (2000) The lipopolysaccharide barrier: correlation of antibiotic susceptibility with antibiotic permeability and fluorescent probe binding kinetics. Biochemistry 39, 11777-11787
35. Chorny, A., and Delgado, M. (2008) Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am. J. Pathol. 172, 1297-1307
36. Abad, C., Martinez, C., Juarranz, M. G., Arranz, A., Leceta, J., Delgado, M., and Gomariz, R. P. (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124, 961-971 (Pubitemid 36389799)
37. Delgado, M., Martinez, C., Pozo, D., Calvo, J. R., Leceta, J., Ganea, D., and Gomariz, R. P. (1999) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162, 1200-1205 (Pubitemid 29035454)
38. McGwire, B. S., and Kulkarni, M. M. (2010) Interactions of antimicrobial peptides with Leishmania and trypanosomes and their functional role in host parasitism. Exp. Parasitol. 126, 397-405
39. McConville, M. J., Homans, S. W., Thomas-Oates, J. E., Dell, A., and Bacic, A. (1990) Structures of the glycoinositolphospholipids from Leishmania major: a family of novel galactofuranose-containing glycolipids. J. Biol. Chem. 265, 7385-7394
40. Ma, D., Russell, D. G., Beverley, S. M., and Turco, S. J. (1997) Golgi GDPmannose uptake requires Leishmania LPG2. A member of a eukaryotic family of putative nucleotide-sugar transporters. J. Biol. Chem. 272, 3799-3805
41. Baltzer, S. A., and Brown, M. H. (2011) Antimicrobial peptides: promising alternatives to conventional antibiotics. J. Mol. Microbiol. Biotechnol. 20, 228-235
42. Iyer, R., Iverson, T., Accardi, A., and Miller, C. (2002) A biological role for prokaryotic ClC chloride channels. Nature 419, 715-718 (Pubitemid 35177955)
43. Sun, Q.-Q., Prince, D. A., and Huguenard, J. R. (2003) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide activate hyperpolarization-activated cationic current and depolarize thalamocortical neurons in vitro. J. Neurosci. 23, 2751-2758 (Pubitemid 36418610)
44. He, J., Eckert, R., Pharm, T., Simanian, M. D., Hu, C., Yarbrough, D. K., Qi, F., Anderson, M. H., and Shi, W. (2007) Novel synthetic antimicrobial peptides against Streptococcus mutans. Antimicrob. Agents Chemother. 51, 1351-1358 (Pubitemid 46586816)
45. Epand, R. F., Schmitt, M. A., Gellman, S. H., Sen, A., Auger, M., Hughes, D. W., and Epand, R. M. (2005) Bacterial species selective toxicity of two isomeric alpha/beta-peptides: role of membrane lipids. Mol. Membr. Biol. 22, 457-469 (Pubitemid 43030902)
46. Delgado, M., Pozo, D., and Ganea, D. (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56, 249-290 (Pubitemid 38720831)
47. Mor, A. (2009) Multifunctional host defense peptides: antiparasitic activities. FEBS J. 276, 6474-6482
48. Naderer, T., Vince, J. E., and McConville, M. J. (2004) Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host. Curr. Mol. Med. 4, 649-665 (Pubitemid 39172369)
49. Yao, C., Donelson, J. E., and Wilson, M. E. (2003) The major surface protease (MSP or GP63) of Leishmania sp.: biosynthesis, regulation of expression, and function. Mol. Biochem. Parasitol. 132, 1-16 (Pubitemid 37239002)
50. Kulkarni, M. M., McMaster, W. R., Kamysz, E., Kamysz, W., Engman, D. M., and McGwire, B. S. (2006) The major surface metalloprotease of the parasitic protozoan, Leishmania, protects against antimicrobial peptideinduced apoptotic killing. Mol. Microbiol. 62, 1484-1497 (Pubitemid 44707208)
51. Kleczka, B., Lamerz, A. C., van Zandbergen, G., Wenzel, A., Gerardy-Schahn, R., Wiese, M., and Routier, F. H. (2007) Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence. J. Biol. Chem. 282, 10498-10505 (Pubitemid 47093425)
52. Reiner, S. L., and Locksley, R. M. (1995) The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13, 151-177
53. Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., and Natanson, C. (2002) Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (Pubitemid 35222596)
54. Hancock, R. E. (1997) Peptide antibiotics. Lancet 349, 418-422 (Pubitemid 27077684)
55. Friedrich, C. L., Moyles, D., Beveridge, T. J., and Hancock, R. E. (2000) Antibacterial action of structurally diverse cationic peptides on Grampositive bacteria. Antimicrob. Agents Chemother. 44, 2086-2092 (Pubitemid 30484431)
56. Medzhitov, R., and Janeway, C., Jr. (2000) Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89-97 (Pubitemid 30095213)
57. Pulido, D., Moussaoui, M., Andreu, D., Nogués, M. V., Torrent, M., and Boix, E. (2012) Antimicrobial action and cell agglutination by the eosinophil cationic protein are modulated by the cell wall lipopolysaccharide structure. Antimicrob. Agents Chemother. 56, 2378-2385